分子病理学研究组

http://sysadmin.xun-ao.com/d/file/2016-12-01/4139ffd8820b43954465fac6fe735105.png 负责人:李锦军研究员

李锦军,男, 19641月生,博士、研究员、博士生导师。 

1997年获日本国立山口大学博士学位,现任上海交通大学医学院附属仁济医院/上海市肿瘤研究所/癌基因及相关基因国家重点实验室研究团队负责人。上海市医学会肿瘤靶分子专业委员会委员、肿瘤专业委员会委员。目前承担国家自然科学基金面上项目2项、十二五国家科技重大专项课题1项,参加973项目1项。2011-2015年期间,发表SCI论文39篇(其中通讯作者13篇,包括2Hepatology1Cancer Res1Mol Cancer Therap杂志文章),参编专著1部。申报国家发明专利12项(其中6项已授权)。2006年享受国务院特殊津贴,2009年入选市优秀学科带头人培养计划(A类)、上海领军人才地方培养计划,新世纪百千万人才工程国家级人才培养计划。2012年开始任上海市政协委员。

 

主要研究方向:

1.肝癌干细胞的靶向治疗临床基础研究;

2.肝癌耐药分子机制研究;

3.肿瘤转移分子机制研究。


Section of Molecular Pathology

 Prof. Jinjun Li Ph.D.

 

Prof. Jin-jun Li obtained his Ph.D degree from The United Graduate School of Veterinary Science, National Yamaguchi University (Doctoral Course) of Japan in 1997. In March, 1999, Dr. Li was recruited to State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University. Dr. Li has been appointed as assistant professor, associate professor and now as PI and professor of Section of Molecular Pathology in the State Key Laboratory of Oncogenes and Related Genes. Between 2011-2015, He has published 39 papers in SCI cited journals such as Hepatology, Cancer Research, Mol Cancer Res, etc. Dr. Li was awarded for third grade prize of Shanghai Science and Technology in 2014, second grade prize of Natural Science Award for Ministry of education of China in 2013, and so on. Dr. Li now focus on basic researches as follows: experimental HCC cancer stem cells targeting therapy, drug resistance and molecular mechanism of liver cancer metastasis by using cellular & pathological, proteomic as well as molecular techniques and platforms. 

 

Research interests

1Clinical basic targeting therapy of hepatocellular carcinoma;

2Molecular mechanism of drug resistance for hepatocellular carcinoma;

3Molecular mechanism of tumor metastasis.

 

李锦军课题组人员集体合影-20151010.JPG